Linked Data API

Show Search Form

Search Results

1104692
registered interest false more like this
date less than 2019-03-25more like thismore than 2019-03-25
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many oncology patients have been registered to receive treatment through the NHS in each year since 2010. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 236365 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage more like this
grouped question UIN
236367 more like this
236369 more like this
question first answered
less than 2019-04-02T11:24:26.92Zmore like thismore than 2019-04-02T11:24:26.92Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1104694
registered interest false more like this
date less than 2019-03-25more like thismore than 2019-03-25
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how much the NHS spent on providing oncological treatment in each year since 2010. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 236367 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage more like this
grouped question UIN
236365 more like this
236369 more like this
question first answered
less than 2019-04-02T11:24:27Zmore like thismore than 2019-04-02T11:24:27Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1104696
registered interest false more like this
date less than 2019-03-25more like thismore than 2019-03-25
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many IT systems are used within oncological treatment in the NHS. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 236369 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage more like this
grouped question UIN
236365 more like this
236367 more like this
question first answered
less than 2019-04-02T11:24:27.077Zmore like thismore than 2019-04-02T11:24:27.077Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1059620
registered interest false more like this
date less than 2019-02-12more like thismore than 2019-02-12
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what assessment they have made of the claims by Accelerated Evolution Biotechnologies of the potential for treating a wide range of cancers with a multi-target toxin treatment. more like this
tabling member printed
Lord Campbell-Savours more like this
uin HL13642 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-26more like thismore than 2019-02-26
answer text <p>On its website, Accelerated Evolution Biotechnologies Ltd presents a technology platform to identify promising peptides that can target cancer cells. All other information on multi-target toxin, (MuTaTo), which is a product combining several cancer-targeting peptides with a strong peptide toxin, which would be personalised to each patient and kill cancer cells specifically - is derived from interviews to newspapers. As no publication of the company’s preliminary works (in vitro and in animals) is available from scientific journals, neither scientific experts nor the Medicines and Healthcare products Regulatory Agency (MHRA) is able to make any assessment of this therapy. The company claims that it is about to start clinical trials, but currently, no clinical trial with such a compound is registered in the European Union public register. If, in the future, the company wishes to apply for a Marketing Authorisation when results in patients become available, the MHRA will be able to assess the quality, safety and efficacy of this therapy and its risk and benefit for its use.</p>
answering member printed Baroness Blackwood of North Oxford more like this
question first answered
less than 2019-02-26T13:36:54.473Zmore like thismore than 2019-02-26T13:36:54.473Z
answering member
4019
label Biography information for Baroness Blackwood of North Oxford more like this
tabling member
499
label Biography information for Lord Campbell-Savours more like this
1002558
registered interest false more like this
date less than 2018-11-06more like thismore than 2018-11-06
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of the NHS long-term plan to (a) tackle the evolving challenges of cancer and (b) ensure that people are able to access personalised and tailored support after they have finished cancer treatment itself. more like this
tabling member constituency Crawley more like this
tabling member printed
Henry Smith more like this
uin 188796 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-14more like thismore than 2018-11-14
answer text <p>The NHS Long Term Plan provides an excellent opportunity to look at how cancer and other services can be further improved over the next decade. The plan is currently in development and will be published later in the year.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-14T11:29:49.547Zmore like thismore than 2018-11-14T11:29:49.547Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
3960
label Biography information for Henry Smith more like this
997164
registered interest false more like this
date less than 2018-10-29more like thismore than 2018-10-29
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, on what date CAR-T therapy for adult cancer patients will be made available. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 184984 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-01more like thismore than 2018-11-01
answer text <p>NHS England is working with the manufacturers and National Health Service providers to prepare the NHS to begin delivering Chimeric Antigen Receptor T Cell (CAR-T) therapy - the first in a wave of treatments in a new era of personalised medicine and part of the NHS’s long-term plan to upgrade cancer service. The first treatment that will be available to patient is tisagenlecleucel (Kymriah) as an option for treating children and young people up to 25 years old with B cell acute lymphoblastic leukaemia that is refractory, in relapsed post-transplant or in second or later relapse.</p><p> </p><p>NHS England anticipates that the National Institute for Health and Care Excellence will recommend this treatment for entry into the Cancer Drugs Fund in mid-November. If so, funding will be made immediately available, following a successful commercial deal with the manufacturer Novartis. We anticipate the first patients will begin their treatment in late November 2018. The phased implementation required by the manufacturer and the NHS means that full capacity to treat eligible patients will take some months to achieve and a National CAR-T Clinical Panel will convene in mid-November to assure equity of access and prioritise eligible patients.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN 184985 more like this
question first answered
less than 2018-11-01T16:55:17.567Zmore like thismore than 2018-11-01T16:55:17.567Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
997165
registered interest false more like this
date less than 2018-10-29more like thismore than 2018-10-29
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, when CAR-T therapy for adult cancer patients will be made available for patients in Torbay and Plymouth hospitals. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 184985 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-01more like thismore than 2018-11-01
answer text <p>NHS England is working with the manufacturers and National Health Service providers to prepare the NHS to begin delivering Chimeric Antigen Receptor T Cell (CAR-T) therapy - the first in a wave of treatments in a new era of personalised medicine and part of the NHS’s long-term plan to upgrade cancer service. The first treatment that will be available to patient is tisagenlecleucel (Kymriah) as an option for treating children and young people up to 25 years old with B cell acute lymphoblastic leukaemia that is refractory, in relapsed post-transplant or in second or later relapse.</p><p> </p><p>NHS England anticipates that the National Institute for Health and Care Excellence will recommend this treatment for entry into the Cancer Drugs Fund in mid-November. If so, funding will be made immediately available, following a successful commercial deal with the manufacturer Novartis. We anticipate the first patients will begin their treatment in late November 2018. The phased implementation required by the manufacturer and the NHS means that full capacity to treat eligible patients will take some months to achieve and a National CAR-T Clinical Panel will convene in mid-November to assure equity of access and prioritise eligible patients.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN 184984 more like this
question first answered
less than 2018-11-01T16:55:17.647Zmore like thismore than 2018-11-01T16:55:17.647Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this
983343
registered interest false more like this
date less than 2018-10-08more like thismore than 2018-10-08
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the reasons for (a) the NHS and (b) individual NHS trusts not meeting the target of 85 per cent of patients starting treatment for cancer within 62 days of an urgent GP referral for suspected cancer. more like this
tabling member constituency Ashfield more like this
tabling member printed
Gloria De Piero more like this
uin 176194 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-10-11more like thismore than 2018-10-11
answer text <p>No formal assessment has been made on the reasons for the National Health Service and individual NHS trusts not meeting the target of 85% of patients starting treatment for cancer within 62 days of an urgent general practitioner (GP) referral for suspected cancer.</p><p> </p><p>There has been a continuing rise in demand for cancer services, with urgent GP referrals for cancer rising by over 70,000 compared to last year (2016-17 compared to 2017-18).</p><p> </p><p>Achieving the 62-day standard was a key objective in the Government’s mandate to NHS England for 2017-18 and this has been rolled forward into 2018-19. The NHS is committed to achieving the 62-day cancer waiting times standard, and to maintaining performance against the other cancer waiting times standards. It is investing this year in initiatives to recover and maintain the 62-day standard nationally, such as pathway coordinators and timed, standardised pathways.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-10-11T16:41:27.443Zmore like thismore than 2018-10-11T16:41:27.443Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
3915
label Biography information for Gloria De Piero more like this
968149
registered interest false more like this
date less than 2018-09-05more like thismore than 2018-09-05
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many and what proportion of cancer patients received treatment within the 62-day target after an urgent GP referral in each region in each of the last five years. more like this
tabling member constituency Easington more like this
tabling member printed
Grahame Morris more like this
uin 170803 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-09-14more like thismore than 2018-09-14
answer text <p>NHS England publishes quarterly performance data on cancer waiting times standards. This includes the numbers and proportion of patients treated within the 62-day urgent general practitioner (GP) referral to a first treatment for cancer 85% standard, by each clinical commissioning group. This data is attached on an annual basis for the last five years (2013-14 to 2017-18).</p><p> </p><p>There has been a continuing rise in demand for cancer services, with urgent GP referrals for cancer rising by over 43% comparing 2013-14 to 2017-18.</p> more like this
answering member constituency North East Cambridgeshire more like this
answering member printed Stephen Barclay more like this
question first answered
less than 2018-09-14T11:10:59.953Zmore like thismore than 2018-09-14T11:10:59.953Z
answering member
4095
label Biography information for Steve Barclay more like this
attachment
1
file name PQ170803 - Grahame Morris - 62 day GP referral annual data 2.xlsx more like this
title PQ170803 more like this
tabling member
3973
label Biography information for Grahame Morris more like this
947399
registered interest false more like this
date less than 2018-07-24more like thismore than 2018-07-24
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to reduce the time taken for GP referrals of patients for cancer treatment. more like this
tabling member constituency Southampton, Itchen more like this
tabling member printed
Royston Smith more like this
uin 168143 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-09-10more like thismore than 2018-09-10
answer text <p>General practitioners are highly skilled healthcare professionals, with the knowledge, training and expertise to treat patients and their presenting conditions. They are required to follow the latest best practice guidance issued by the National Institute of Health and Care Excellence, as well as making appropriate and timely referrals for diagnostics and/or secondary and tertiary care.</p><p> </p><p>Improving early diagnosis of cancer is a priority for NHS England. Cancer Alliances have been established across the country to act as leaders across their locality to drive transformation and have clear oversight over the whole patient pathway. In December 2016, NHS England announced that £200 million would be made available to Cancer Alliances over two years (2017/18 and 2018/19) to support transformation in early diagnosis and support for people living with a cancer diagnosis.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-09-10T16:57:25.797Zmore like thismore than 2018-09-10T16:57:25.797Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4478
label Biography information for Royston Smith more like this